Article Text

Download PDFPDF
Randomised controlled trial
Lactobacillus rhamnosus GG reduces frequency and severity of abdominal pain compared with placebo in children with irritable bowel syndrome
  1. Markus A Rose
  1. Department of Pulmonology, Allergy & Infectious Diseases, Goethe University, Children's Hospital, Frankfurt, Germany
  1. Correspondence to Markus A Rose
    Goethe University, Children's Hospital, Theodor Stern Kai 7, D-60590 Frankfurt, Germany; markus.rose{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlAbstract/FREE Full Text


Recurrent abdominal pain (RAP) is among the most frequent functional disorders in children, consuming immense healthcare resources. Therapeutic approaches are difficult and often unsatisfying. Probiotics are live microorganisms that are perceived to benefit the host beyond their inherent basic nutrition. They have been shown to have beneficial effects on various aspects of human health, and their success in treating childhood diarrhoea and certain chronic inflammatory bowel diseases has led to increased interest in their use in patients with RAP. The rationale is based on trials suggesting a role for intestinal infection, inflammation and food allergies in the pathogenesis of the disorder and observed beneficial effects of probiotics on these pathomechanisms.1 Despite growing interest in and availability of probiotic foods and products, data from systematic trials …

View Full Text


  • Competing interests MAR has received lecture fees and unrestricted scientific grants from Symbiopharm, Danone and Infectopharm – manufacturers/distributors of probiotics.